Established in 2016, the Immuno-Histology Core performs state-of-the-art tissue and image analysis for preclinical and clinical translational studies at Providence Cancer Institute. Under the direction of William L. Redmond, Ph.D., and Zhaoyu Sun, Ph.D., the immuno-histology team possesses an advanced understanding of immunohistochemistry as applied to research, preclinical and clinical evaluations and management, with expertise in immuno-histology, quantitative image analysis, and multiplex immunofluorescence staining.
At the forefront of immunohistochemistry technology, the team advises intramural investigators on imaging techniques to accomplish their research goals. They oversee the development and deployment of new antibodies, evaluate new methods and techniques, and perform quality control analysis.
They also develop protocols and provide standard operating procedures for histology staining procedures and immunostaining based on current technologies and techniques, such as protocols for multiplex immunohistochemistry / immunofluorescence on human formalin-fixed paraffin-embedded pathological tissue samples that allow for the successful staining of six biomarkers sequentially on a single tissue slide. This technology is critical to elucidating the mechanisms of cancer immunotherapy.
The Immuno-Histology Core is equipped with a Vectra 3.0 Automated Quantitative Pathology Imaging System (pictured left) and a Zeiss Z1 Motorized Stage Fluorescence Microscope; Sakura Tissue-Tek and Leica Embedder and RM2235 Rotary Microtome for tissue processing, embedding and sectioning; Ventana Discovery Ultra and Leica auto strainers; and a TMA Master for tissue microarray.